Who we are

CIS region has undergoing major changes in regulatory framework related to Eurasian Economic Union (EAEU) regulations. PharmaLex is a global company with local representatives operating all over the globe region, including CIS. We have established and maintained a global network of local representatives in the CIS region since 2012.

  • Countries: Russia, Kazakhstan, Uzbekistan, Tajikistan, Kyrgistan, Mongolia, Turkmenistan, Ukraine, Belarus, Georgia, Azerbaijan, Armenia and Moldova.
  • Well-established local representatives with local expertise and connections.
  • Established access and f2F meetings with the Health Authorities, such as FGBU (Russia).
  • We cover all of the services offered by PharmaLex across the CIS region, including end-to-end services from the pre-submission regulatory strategy, to the marketing authorisation and the life cycle management activities.

For customers looking for support in the CIS region, PharmaLex offers the option to have a single point of contact, who will manage and oversee entire functions as well as manage the liaison between our customers and our local experts on site.

Local Contact

  • Laura Monkiene
    Director, Principal Consultant Regulatory Affairs

What our clients say about us

We are working with a number of large pharma companies and are looking to create a consortium of partners to collect feedback on expertise, availability and outcomes. If you would be interested in joining our consortium, please contact us on contact@pharmalex.com.

  • During the bid defense we felt that you worked well as team and are very dynamic. Preparation of such a complex dossier really needs to be done in such a way.

    Large Pharma, Germany
    VP Regulatory Affairs
  • What was especially important to me was their ability to get a team, with the right experience, together so quickly.

    Mid-size Biotech
    Head of Outsourcing
  • We really appreciate your responsiveness and availability during our previous exchanges and it is what we are waiting for from our partner.

    Small Medium Sized Company, UK
    Head of Regulatory Affairs
  • There was a close relationship between the regulatory strategy and the writing activities. You developed a fine-tuned regulatory strategy which will be a key factor to smooth the approval of our dossier.

    Large Pharma, Global
    VP Regulatory Strategy